OP Business Summary

Orient Pharma Co., Ltd. (4166.TWO) is a Taiwan-based specialty pharmaceutical company that generates revenue through the research, development, and global commercialization of value-added 505(b)(2) drugs and complex generics. The company’s business model is bifurcated into proprietary product sales—focusing on therapeutic areas such as neuroscience (ADHD, Parkinson's), cardiovascular diseases, and autoimmune disorders—and high-margin Contract Development and Manufacturing Organization (CDMO) services. Utilizing its proprietary Multi-Phasic Release Technology (MPRT), Orient Pharma produces a diverse portfolio of oral solid dosages, including its flagship ADHD treatment Methydur and the long-acting rheumatoid arthritis drug Tofacitinib XR, which is slated for a major U.S. market launch in mid-2026. Within the competitive landscape, the company contends with major Taiwanese peers such as Bora Pharmaceuticals, Lotus Pharmaceutical, and PharmaEssentia, positioning itself as a niche leader in controlled-release drug delivery and a critical manufacturing hub for the broader Orient Europharma (OEP) Group. The company was founded in 2008 by Chairman Peter Tsai (Tsai Wu-hsiung), a veteran of the pharmaceutical industry who previously served as a top executive at Pfizer’s Upjohn division before establishing the parent group, Orient Europharma, in 1982. Current leadership is headed by CEO and General Manager Chun-Tong Huang, supported by Chief Scientific Officer Wen-Chin Tsai, PhD, and Head of R&D Mac Sriwongjanya, PhD, who oversee the firm’s advanced formulation and clinical development pipelines. The executive team is further bolstered by Calvin Tsai, who serves as CEO of the OEP Group and maintains a strategic role on the board of directors. Orient Pharma remains a core subsidiary of Orient Europharma Co., Ltd. (4120.TT), which provides significant institutional backing and an integrated distribution network across the Asia-Pacific and North American regions.